ITMO Santé Publique
ITMO Santé Publique
Date de modification : 08/07/2015 | Version : 2 | ID : 5075
| Général | |
| Identification | |
| Nom détaillé | French Multicentric Cohort on Genetic, Epigenetic and Environmental Risk Factors of Autoimmune Diabetes and its Complications. |
| Sigle ou acronyme | ISIS-DIAB |
| Numéro d'enregistrement (ID-RCB ou EUDRACT, CNIL, CPP, etc.) | CNIL n°909186, DR-2010-0035 / CPPn°DC-2008-693, NI 2620 09/12/2008 / CCTIRS n°08.402 11/09/2008 |
| Thématiques générales | |
| Domaine médical |
Endocrinology and metabolism |
| Déterminants de santé |
Climate Genetic Geography Nutrition Occupation Pollution Social and psychosocial factors |
| Mots-clés | Genetic environment |
| Responsable(s) scientifique(s) | |
| Nom du responsable | Bougneres |
| Prénom | Pierre |
| Adresse | Site de l’hôpital Bicêtre, Bât G.Pincus 1er étage 80, rue du Général Leclerc 94276 Le Kremlin Bicêtre cedex |
| Téléphone | + 33 (0)1 49 59 53 50 |
| Pierre.bougneres@inserm.fr | |
| Laboratoire | U986 : Immunologie et génétique du diabète de type 1, génétiquemultifactorielle en endocrinologie pédiatrique |
| Organisme | INSERM - Institut National de la Santé et de la Recherche |
| Nom du responsable | Valleron |
| Prénom | Alain- Jacques |
| Adresse | Site de l’hôpital Bicêtre, Bât G.Pincus 1er étage 80, rue du Général Leclerc 94276 Le Kremlin Bicêtre cedex |
| Téléphone | + 33 (0)1 49 59 53 50 |
| alain-jacques.valleron@inserm.fr | |
| Laboratoire | U986 : Immunologie et génétique du diabète de type 1, génétiquemultifactorielle en endocrinologie pédiatrique |
| Organisme | INSERM - Institut National de la Santé et de la Recherche |
| Collaborations | |
| Financements | |
| Financements |
Mixed |
| Précisions | Inserm/NovoNordisk (ALLIANCE) |
| Gouvernance de la base de données | |
| Organisation(s) responsable(s) ou promoteur | INSERM - Institut National de la Santé et de la Recherche Médicale |
| Statut de l’organisation |
Secteur Public |
| Contact(s) supplémentaire(s) | |
| Caractéristiques | |
| Type de base de données | |
| Type de base de données |
Study databases |
| Base de données issues d'enquêtes, précisions |
Cohort study |
| Origine du recrutement des participants |
A selection of health institutions and services |
| Le recrutement dans la base de données s'effectue dans le cadre d'une étude interventionnelle |
No |
| Informations complémentaires concernant la constitution de l'échantillon | Cases are recruited from paediatric or diabetology departments who agreed to participate in the study. |
| Objectif de la base de données | |
| Objectif principal |
To conduct gene-environment studies on a large scale, with a "data driven" methodology (GWAS for the genetic portion, questionnaires with no preconceived ideas and French environmental databases for the environmental portion), in order to identify risk factors of type 1 diabetes as well as its acute (severe hypoglycaemia, ketoacidosis) and chronic (retinopathy, nephropathy) complications. To conduct epigenetic studies by investigating methylation development (candidate genes or the entire genome) according to different phenotypic traits (glycaemic control, onset of complications, insulin dosage).To be the basis of immune modulation studies for all early diabetes, or for patients resistant to autoimmune attack, and to keep a significant reserve of functional beta cells for 1-5 years (European project DF-IL2, through collaboration with D. Klatzman, funded by FP7 clinical trial tender).
ISIS provides the infrastructure to enable the recruitment of newly diagnosed diabetes cases (149 new cases of diabetes recruited in 2008, 136 in 2009, 143 in 2010 and 191 in 2011). To investigate the beginning of microangiopathic complications in a significant number of children and to study the medical, genetic, epigenetic and environmental determinants of these complications by an integrated and multi-factorial approach. Patients currently in the ISIS cohort have had diabetes for an average of 10.8 years and a mean HbA1c of 8.4%. Background retinopathy is expected in approximately 20% of those that have had diabetes over 10 years (at present: 1,581 cohort patients have had diabetes for more than 10 years, approximately 300 patients are expected to develop complications). We also wish to initiate a strategy for prospective primary prevention trials for retinopathy in 2012 in collaboration with Prof. P. Massin. To conduct studies on conventional treatment and improvements that can be initiated. Our main focus is to test therapeutic education procedures that can limit inequalities in treatment quality and promote "minimally disruptive" medical practice (May C, Montori VM, Fair FS: We need minimally disruptive medicine, BMJ 2009; 339: b2803) capable of minimising the therapeutic burden added to chronic disease, in contrast with the rampant intensification of treatment practised by some that we believe now threatens the quality of psychological development of a significant proportion of young children with diabetes. To conduct prospective studies on sudden death syndrome, "dead in bed" characteristics of adolescents with diabetes (O'Reilly M, O'Sullivan EP, Davenport C, Smith D: « Dead in bed » : a tragic complication of type 1 diabetes mellitus, Ir J Med Sci 2010, 179 (4): 585-7), risk factors for mortality and morbidity in severe ketoacidosis (special youth complications). Such studies do not exist in the literature: important case-based reasoning is necessary to answer these two questions. This explains the limited nature of the studies in the literature that relied on a small series of anecdotal and retrospective cases. To conduct humanities and social science studies in the field of psychological consequences of childhood diabetes, including the frequency of depressive syndromes (patients and parents) and to analyse health care access disparities (incorporating geographical, medical and sociological analyses). To broaden the scope of cohort-related work by screening case families for diabetes (there are about 5,200 brothers or sisters under 7 years of age related to diabetic children already included in ISIS). |
| Critères d'inclusion | French people with type 1 diabetes |
| Type de population | |
| Age |
Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population concernée |
Sick population |
| Sexe |
Male Woman |
| Champ géographique |
National |
| Détail du champ géographique | France |
| Collecte | |
| Dates | |
| Année du premier recueil | 2006 |
| Taille de la base de données | |
| Taille de la base de données (en nombre d'individus) |
[10 000-20 000[ individuals |
| Détail du nombre d'individus | 10000 |
| Données | |
| Activité de la base |
Current data collection |
| Type de données recueillies |
Clinical data Declarative data Biological data |
| Données cliniques, précisions |
Direct physical measures |
| Données déclaratives, précisions |
Paper self-questionnaire Phone interview |
| Données biologiques, précisions | DNA |
| Existence d’une biothèque |
Yes |
| Contenu de la biothèque |
Plasma DNA |
| Détail des éléments conservés | Blood samples were pretreated: separation of plasma for plasma bank and lymphocytes for DNA extraction. Biobank is kept at -80°C. |
| Paramètres de santé étudiés |
Health event/morbidity Health event/mortality |
| Modalités | |
| Mode de recueil des données | Clinical data are collected in patient clinical records every 6 months from enrolment date Biological data collected at baseline (blood sample for DNA extraction and plasma bank, transportation at +4°C by a professional carrier, treatment and storage) environmental data collected through a questionnaire sent to patients in the month following their enrolment (+ telephone follow-up if needed) |
| Suivi des participants |
Yes |
| Détail du suivi | Clinical parameter follow-up |
| Appariement avec des sources administratives |
No |
| Valorisation et accès | |
| Valorisation et accès | |
| Lien vers le document | http://tinyurl.com/Pubmed-ISIS-DIAB |
| Description | List of publications in Pubmed |
| Accès | |
| Charte d'accès aux données (convention de mise à disposition, format de données et délais de mise à disposition) | Contact the scientist in charge |
| Accès aux données agrégées |
Access on specific project only |
| Accès aux données individuelles |
Access on specific project only |
| A PROPOS | CATALOGUE | RESSOURCES | LIENS UTILES
|  Ce site respecte les principes de la charte HONcode. Vérifiez ici. |
8 rue de la Croix Jarry 75013 Paris Tél: 01 44 23 67 47 |
Partenaires - F.A.Q. - Contact - Plan du site - Mentions légales - Administration - PEF-HD - Mis à jour le 15 décembre 2020 - Version 4.10.05
